// App-Quantinova.ai

POS1033 (2022) : DYNAMICS OF NAIL PSORIASIS WITH GUSELKUMAB TREATMENT AND WITHDRAWAL IN ASSOCIATION WITH SKIN RESPONSE AND PATIENT-REPORTED OUTCOMES: A POST HOC ANALYSIS OF THE VOYAGE 2 PHASE 3 TRIAL

Researchers

Presenter

  • W. Tillett

Principal Investigators

  • A. Egeberg

  • E. Sonkoly

  • P. Gorecki

  • A. Tjrnlund

  • J. Buyze

  • S. Wegner

  • D. Mcgonagle

Medical Centers

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • University of Bath, Pharmacy and Pharmacology, Bath, United Kingdom

  • Bispebjerg Hospital, Department of Dermatology, Copenhagen, Denmark

  • Karolinska Institutet, Dermatology and Venereology Division, Stockholm, Sweden

  • Karolinska Institutet, Center for Molecular Medicine, Stockholm, Sweden

  • Uppsala University, Department of Medical Sciences, Uppsala, Sweden

  • Janssen Cilag, High Wycombe, United Kingdom

  • , Janssen-Cilag, Solna, Sweden

  • Janssen-Cilag BV, Breda, Netherlands

  • Janssen-Cilag GmbH,, Neuss, Netherlands

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • Leeds Teaching Hospitals, National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, United Kingdom

Locations

  • United Kingdom

  • Denmark

  • Sweden

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • OPEN Health Medical Communications

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved